Not Even Tripping

JRT: The LSD Analogue That Repairs the Brain Without the Trip

Published April 2026

Imagine a molecule that delivers many of the powerful therapeutic benefits associated with LSD — rapid brain repair, new neural connections, and potent antidepressant effects — but without the intense hallucinations. Researchers at the University of California, Davis have created exactly that: a groundbreaking compound called (+)-JRT.

The Origin of the Name: In chemistry, it’s a long-standing tradition to name a new compound after the scientist who first synthesized it. JRT stands for Jeremy R. Tuck, the lead researcher at UC Davis who spent five years perfecting the complex 12-step synthesis required to bring this molecule to life.

The "Tire Rotation" That Changed Everything

Lead researcher Dr. David E. Olson described the innovation as a molecular “tire rotation.” By transposing just two atoms in the structure of LSD, they created an isotryptamine version of the drug.

“By just transposing two atoms in LSD, we significantly improved JRT’s selectivity profile and reduced its hallucinogenic potential.”

While JRT shares the same molecular weight and shape as classic LSD-25, this subtle "flip" changes how it docks with the 5-HT2A receptor. It maintains the signaling that triggers neuroplasticity (brain cell growth) while muting the pathways that cause hallucinations.

What the Preclinical Studies Show

In animal models, JRT has shown results that could make it a "heavyweight" in neuro-psychiatry:

+46% Increase in dendritic spine density within the prefrontal cortex.
100x More potent antidepressant-like effects than ketamine in specific trials.
0 Hallucinogenic markers observed, making it a "non-hallucinogenic psychoplastogen."

A New Frontier for Schizophrenia

Traditional psychedelics are typically high-risk for schizophrenia patients due to the potential for psychosis. Because JRT acts specifically on the 5-HT2A receptor without the "trip," it offers a potential breakthrough for:

  • Negative and cognitive symptoms of Schizophrenia
  • Treatment-resistant depression
  • PTSD and trauma-related brain injury
  • Alzheimer’s and Parkinson’s disease

The Future of Neuroplastogens

Jeremy Tuck’s five-year effort to build this molecule could change psychiatry. If human trials confirm these results, JRT might lead to a future where brain repair is as simple as taking a non-drowsy allergy pill—no clinical "trip" required.

What do you think? Is the industry ready for non-hallucinogenic psychedelics? Let’s hear your thoughts in the comments.

Disclaimer: This post is for informational purposes only and does not constitute medical advice.

Sources: Jeremy R. Tuck et al., PNAS (2025); UC Davis News.

Comments

Popular posts from this blog

Legal Texas Cannabis — Hemp Legalities And Use

Help Me With This Nerve Pain

Zinc Ionophores: Boosting Zinc’s Antiviral Power